The role of intravenous iron in anemia management and transfusion avoidance. (opens new window)

Auerbach M, Goodnough LT, Picard D, Maniatis A.

Źródło‎: Transfusion 2008;48(5):988-1000.

Indeks‎: PubMed 18346021

DOI‎: 10.1111/j.1537-2995.2007.01633.x

https://www.ncbi.nlm.nih.gov/pubmed/18346021 (opens new window)

The short-term use of erythropoetin-stimulating agents: impact on the biochemical recurrence of prostate cancer. (opens new window)

Djavan B, Laze J, Eckersberger E, Finkelstein J, Agalliu I, Lepor H.

Źródło‎: BJU Int 2011;108(10):1582-7.

Indeks‎: PubMed 21443653

DOI‎: 10.1111/j.1464-410X.2011.10173.x

https://www.ncbi.nlm.nih.gov/pubmed/21443653 (opens new window)

The preoperative use of erythropoietin stimulating proteins prior to radical prostatectomy is not associated with increased cardiovascular or thromboembolic morbidity or mortality. (opens new window)

Lepor H, Lipkin M, Slova D.

Źródło‎: Urology 2010;75(6):1424-8.

Indeks‎: PubMed 20513505

DOI‎: 10.1016/j.urology.2009.06.095

https://www.ncbi.nlm.nih.gov/pubmed/20513505 (opens new window)

Comparison of two different doses of preoperative recombinant erythropoietin in men undergoing radical retropubic prostatectomy. (opens new window)

Nieder AM, Rosenblum N, Lepor H.

Źródło‎: Urology 2001;57(4):737-41.

Indeks‎: PubMed 11306393

https://www.ncbi.nlm.nih.gov/pubmed/11306393 (opens new window)